Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
Recruiting now · Not applicable
Conditions studied: Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR)
In brief
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.
Key facts
- Study ID
- NCT06843499
- Run by
- National Taiwan University Hospital
- People needed
- 1000
- Starts
- 2025-06-02
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-07-22
Who can join
Age: 20 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
- VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
You may not qualify if…
- The patient does not agree to participate in the trial or is unable to provide informed consent.
Where it is running
- National Taiwan University Hospital — Taipei, Taiwan, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.